ClinicalTrials.gg
CompletedNCT02821910Updated Mar 5, 2020Results posted

Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Linagliptin/Metformin Extended Release Compared With Single Tablets

A Phase 1 interventional study of High dose FDC Empagliflozin/Linagliptin/Metformin XR, fed and 1 tab Empagliflozin +1 tab Linagliptin +2 tabs Metformin XR in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-03-05.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this trial is to demonstrate the relative bioavailability of 2 newly developed fixed dose combinations (FDC) tablets containing empagliflozin, linagliptin \& metformin extended release (XR) and the single tablets of empagliflozin, linagliptin and metformin XR administered simultaneously.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male or female subjects according to the investigator's assessment, based on a complete medical history including a physical examination, vital signs (blood pressure, pulse rate), 12-lead , and clinical laboratory tests
  • Age of 18 to 55 years (incl.)
  • of 18.5 to 29.9 kg/m2 (incl.)
  • Signed and dated written prior to admission to the study in accordance with GCP and local legislation
  • Male subjects, or female subjects who meet any of the following criteria starting from at least 30 days before the first administration of trial medication and until 30 days after trial completion:

Use of adequate , e.g. any of the following methods plus condom: implants, injectables, combined oral or vaginal contraceptives, intrauterine device Sexually abstinent A vasectomised sexual partner (vasectomy at least 1 year prior to enrolment) Surgically sterilised (including hysterectomy) , defined as at least 1 year of spontaneous amenorrhea (in questionable cases a blood sample with simultaneous levels of follicle-stimulating hormone above 40 U/L and estradiol below 30 ng/L is confirmatory)

Exclusion criteria

Exclusion criteria:

  • Any finding in the medical examination (including blood pressure, pulse rate or ) is deviating from normal and judged as by the investigator
  • Repeated measurement of systolic blood pressure outside the range of 90 to 140 mmHg, diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the range of 45 to 90 bpm
  • Any laboratory value outside the reference range that the investigator considers to be of clinical relevance
  • Any evidence of a concomitant disease judged as clinically relevant by the investigator
  • Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  • Cholecystectomy and/or surgery of the gastrointestinal tract that could interfere with the pharmacokinetics of the trial medication (except appendectomy and simple hernia repair)
  • Diseases of the central nervous system (including but not limited to any kind of seizures or stroke), and other relevant neurological or psychiatric disorders
  • Further exclusion criteria apply
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    High dose, fed

    1 fixed dose combination (FDC) tablet vs. 4 single tablets under fed conditions

    Drug: High dose FDC Empagliflozin/Linagliptin/Metformin XR, fed · Drug: 1 tab Empagliflozin +1 tab Linagliptin +2 tabs Metformin XR

  • Experimental
    High dose, fasted

    1 fixed dose combination (FDC) tablet vs. 4 single tablets under fasted conditions

    Drug: High dose FDC Empagliflozin/Linagliptin/Metformin XR, fasted · Drug: 1 tab Empagliflozin +1 tab Linagliptin +2 tabs Metformin XR

  • Experimental
    Low dose, fed

    1 fixed dose combination (FDC) tablet vs. 4 single tablets under fed conditions

    Drug: Low dose FDC Empagliflozin/Linagliptin/Metformin XR, fed · Drug: 1 tab Empagliflozin +1 tab Linagliptin +2 tabs Metformin XR

Interventions

  • DrugHigh dose FDC Empagliflozin/Linagliptin/Metformin XR, fed

    High dose Empagliflozin/Linagliptin/Metformin extended release (XR) fixed dose combination (FDC) tablet

  • Drug1 tab Empagliflozin +1 tab Linagliptin +2 tabs Metformin XR

    1x Empagliflozin + 1x Linagliptin + 2x Metformin extended release (XR) tablets

  • DrugHigh dose FDC Empagliflozin/Linagliptin/Metformin XR, fasted

    High dose Empagliflozin/Linagliptin/Metformin extended release (XR) fixed dose combination (FDC) tablet

  • Drug1 tab Empagliflozin +1 tab Linagliptin +2 tabs Metformin XR

    1x Empagliflozin + 1x Linagliptin + 2x Metformin extended release (XR) tablets

  • DrugLow dose FDC Empagliflozin/Linagliptin/Metformin XR, fed

    Low dose Empagliflozin/Linagliptin/Metformin extended release (XR) fixed dose combination (FDC) tablet

  • Drug1 tab Empagliflozin +1 tab Linagliptin +2 tabs Metformin XR

    1x Empagliflozin + 1x Linagliptin + 2x Metformin extended release (XR) tablets

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration-time Curve of Empagliflozin in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Concentration (AUC0-tz)

    Area under the concentration-time curve of Empagliflozin in plasma over the time interval from 0 to the time of the last quantifiable concentration (AUC0-tz) is presented. Plasma concentrations and/or parameters of a subject were considered as non-evaluable, if for example * The subject experienced emesis that occurred at or before 2 times median tmax of the respective treatment (median tmax was to be determined excluding the subject's experiencing emesis) * A pre-dose concentration was \>5% of the Cmax value measured in that subject * Missing samples or concentration data at important phases of PK disposition curve

    Time frame: 1.5 hours (h) before drug administration and 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 5h, 6h, 7h, 8h,10h, 12h, 24h, 34h, 48h, and 72h after drug administration

  2. Area Under the Concentration-time Curve of Metformin in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Concentration (AUC0-tz)

    Area under the concentration-time curve of Metformin in plasma over the time interval from 0 to the time of the last quantifiable concentration (AUC0-tz) is presented

    Time frame: 1.5 hours (h) before drug administration and 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 5h, 6h, 7h, 8h,10h, 12h, 24h, 34h, 48h, and 72h after drug administration

  3. Maximum Measured Concentration of Empagliflozin in Plasma (Cmax)

    Maximum measured concentration of Empagliflozin in plasma (Cmax) is presented

    Time frame: 1.5 hours (h) before drug administration and 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 5h, 6h, 7h, 8h,10h, 12h, 24h, 34h, 48h, and 72h after drug administration

  4. Maximum Measured Concentration of Metformin in Plasma (Cmax)

    Maximum measured concentration of Metformin in plasma (Cmax) is presented

    Time frame: 1.5 hours (h) before drug administration and 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 5h, 6h, 7h, 8h,10h, 12h, 24h, 34h, 48h, and 72h after drug administration

  5. Maximum Measured Concentration of Linagliptin in Plasma (Cmax)

    Maximum measured concentration of Linagliptin in plasma (Cmax) is presented

    Time frame: 1.5 hours (h) before drug administration and 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 5h, 6h, 7h, 8h,10h, 12h, 24h, 34h, 48h, and 72h after drug administration

  6. Area Under the Concentration-time Curve of Linagliptin in Plasma Over the Time Interval From 0 to 72 Hours (AUC0-72)

    Area under the concentration-time curve of Linagliptin in plasma over the time interval from 0 to 72 hours (AUC0-72) is presented

    Time frame: 1.5 hours (h) before drug administration and 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 5h, 6h, 7h, 8h,10h, 12h, 24h, 34h, 48h, and 72h after drug administration

Secondary outcomes

  1. Area Under the Concentration-time Curve of the Empagliflozin in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)

    Area under the concentration-time curve of the Empagliflozin in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞) is presented

    Time frame: 1.5 hours (h) before drug administration and 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 5h, 6h, 7h, 8h,10h, 12h, 24h, 34h, 48h, and 72h after drug administration

  2. Area Under the Concentration-time Curve of the Metformin in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)

    Area under the concentration-time curve of the Metformin in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞) is presented

    Time frame: 1.5 hours (h) before drug administration and 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 5h, 6h, 7h, 8h,10h, 12h, 24h, 34h, 48h, and 72h after drug administration

  3. Area Under the Concentration-time Curve of the Linagliptin in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)

    Area under the concentration-time curve of the Linagliptin in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞) is presented

    Time frame: 1.5 hours (h) before drug administration and 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 5h, 6h, 7h, 8h,10h, 12h, 24h, 34h, 48h, and 72h after drug administration

07

Results

Posted Feb 21, 2020

Participant flow

Participant flow — Overall Study
MilestoneFDC 25 Fed (T1)/ E25+L5+M1000 Fed (R1) (Part 1)E25+L5+M1000 Fed (R1)/ FDC 25 Fed (T1) (Part 1)FDC 25 Fast (T2)/ E25+L5+M1000 Fast (R2) (Part 2)E25+L5+M1000 Fast (R2)/ FDC 25 Fast (T2) (Part 2)FDC 10 Fed (T3)/ E10+L5+M1000 Fed (R3) (Part 3)E10+L5+M1000 Fed (R3)/ FDC 10 Fed (T3) (Part 3)
Started78101078
Completed6881077
Not completed102001
Withdrew: Withdrawal by subject001001
Withdrew: Other than specified101000

Outcome measures

PrimaryArea Under the Concentration-time Curve of Empagliflozin in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Concentration (AUC0-tz)

Area under the concentration-time curve of Empagliflozin in plasma over the time interval from 0 to the time of the last quantifiable concentration (AUC0-tz) is presented. Plasma concentrations and/or parameters of a subject were considered as non-evaluable, if for example * The subject experienced emesis that occurred at or before 2 times median tmax of the respective treatment (median tmax was to be determined excluding the subject's experiencing emesis) * A pre-dose concentration was \>5% of the Cmax value measured in that subject * Missing samples or concentration data at important phases of PK disposition curve

Time frame:
1.5 hours (h) before drug administration and 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 5h, 6h, 7h, 8h,10h, 12h, 24h, 34h, 48h, and 72h after drug administration
Reported as:
Geometric mean · nanomoles (nmol)*hours (h)/litres (L)
Area Under the Concentration-time Curve of Empagliflozin in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Concentration (AUC0-tz)
nanomoles (nmol)*hours (h)/litres (L)FDC 25 Fed (T1)E25+L5+M1000 Fed (R1)FDC 25 Fast (T2)E25+L5+M1000 Fast (R2)FDC 10 Fed (T3)E10+L5+M1000 Fed (R3)
Area Under the Concentration-time Curve of Empagliflozin in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Concentration (AUC0-tz)5990 ± 25.66120 ± 22.86430 ± 20.26250 ± 18.72080 ± 15.42130 ± 15.5
Statistical analysis
  • FDC 25 Fed (T1) vs E25+L5+M1000 Fed (R1) · Ratio (%): 96.70 · 90% CI 92.89 to 100.66Relative bioavailability was estimated by the adjusted gMean ratio of T1 divided by R1. Standard deviation is actually intra-individual geometric coefficient variation (gCV).
  • FDC 25 Fast (T2) vs E25+L5+M1000 Fast (R2) · Ratio (%): 100.80 · 90% CI 97.99 to 103.70Relative bioavailability was estimated by the adjusted gMean ratio of T2 divided by R2. Standard deviation is actually intra-individual geometric coefficient variation (gCV).
  • FDC 10 Fed (T3) vs E10+L5+M1000 Fed (R3) · Ratio (%): 99.83 · 90% CI 95.96 to 103.85Relative bioavailability was estimated by the adjusted gMean ratio of T3 divided by R3. Standard deviation is actually intra-individual geometric coefficient variation (gCV).
PrimaryArea Under the Concentration-time Curve of Metformin in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Concentration (AUC0-tz)

Area under the concentration-time curve of Metformin in plasma over the time interval from 0 to the time of the last quantifiable concentration (AUC0-tz) is presented

Time frame:
1.5 hours (h) before drug administration and 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 5h, 6h, 7h, 8h,10h, 12h, 24h, 34h, 48h, and 72h after drug administration
Reported as:
Geometric mean · nanograms (ng)*h/ milliliter (mL)
Area Under the Concentration-time Curve of Metformin in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Concentration (AUC0-tz)
nanograms (ng)*h/ milliliter (mL)FDC 25 Fed (T1)E25+L5+M1000 Fed (R1)FDC 25 Fast (T2)E25+L5+M1000 Fast (R2)FDC 10 Fed (T3)E10+L5+M1000 Fed (R3)
Area Under the Concentration-time Curve of Metformin in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Concentration (AUC0-tz)13900 ± 29.613900 ± 30.97920 ± 31.38260 ± 33.412000 ± 26.012200 ± 25.9
Statistical analysis
  • FDC 25 Fed (T1) vs E25+L5+M1000 Fed (R1) · Ratio (%): 96.82 · 90% CI 90.65 to 103.42Relative bioavailability was estimated by the adjusted gMean ratio of T1 divided by R1. Standard deviation is actually intra-individual geometric coefficient variation (gCV).
  • FDC 25 Fast (T2) vs E25+L5+M1000 Fast (R2) · Ratio (%): 95.67 · 90% CI 87.44 to 104.68Relative bioavailability was estimated by the adjusted gMean ratio of T2 divided by R2. Standard deviation is actually intra-individual geometric coefficient variation (gCV).
  • FDC 10 Fed (T3) vs E10+L5+M1000 Fed (R3) · Ratio (%): 98.47 · 90% CI 92.12 to 105.25Relative bioavailability was estimated by the adjusted gMean ratio of T3 divided by R3. Standard deviation is actually intra-individual geometric coefficient variation (gCV).
PrimaryMaximum Measured Concentration of Empagliflozin in Plasma (Cmax)

Maximum measured concentration of Empagliflozin in plasma (Cmax) is presented

Time frame:
1.5 hours (h) before drug administration and 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 5h, 6h, 7h, 8h,10h, 12h, 24h, 34h, 48h, and 72h after drug administration
Reported as:
Geometric mean · nmol/L
Maximum Measured Concentration of Empagliflozin in Plasma (Cmax)
nmol/LFDC 25 Fed (T1)E25+L5+M1000 Fed (R1)FDC 25 Fast (T2)E25+L5+M1000 Fast (R2)FDC 10 Fed (T3)E10+L5+M1000 Fed (R3)
Maximum Measured Concentration of Empagliflozin in Plasma (Cmax)594 ± 17.7630 ± 20.4872 ± 24.5817 ± 31.5232 ± 20.5235 ± 18.8
Statistical analysis
  • FDC 25 Fed (T1) vs E25+L5+M1000 Fed (R1) · Ratio (%): 94.94 · 90% CI 86.60 to 104.08Relative bioavailability was estimated by the adjusted gMean ratio of T1 divided by R1. Standard deviation is actually intra-individual geometric coefficient variation (gCV).
  • FDC 25 Fast (T2) vs E25+L5+M1000 Fast (R2) · Ratio (%): 106.63 · 90% CI 100.65 to 112.96Relative bioavailability was estimated by the adjusted gMean ratio of T2 divided by R2. Standard deviation is actually intra-individual geometric coefficient variation (gCV).
  • FDC 10 Fed (T3) vs E10+L5+M1000 Fed (R3) · Ratio (%): 100.41 · 90% CI 94.54 to 106.64Relative bioavailability was estimated by the adjusted gMean ratio of T3 divided by R3. Standard deviation is actually intra-individual geometric coefficient variation (gCV).
PrimaryMaximum Measured Concentration of Metformin in Plasma (Cmax)

Maximum measured concentration of Metformin in plasma (Cmax) is presented

Time frame:
1.5 hours (h) before drug administration and 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 5h, 6h, 7h, 8h,10h, 12h, 24h, 34h, 48h, and 72h after drug administration
Reported as:
Geometric mean · ng/mL
Maximum Measured Concentration of Metformin in Plasma (Cmax)
ng/mLFDC 25 Fed (T1)E25+L5+M1000 Fed (R1)FDC 25 Fast (T2)E25+L5+M1000 Fast (R2)FDC 10 Fed (T3)E10+L5+M1000 Fed (R3)
Maximum Measured Concentration of Metformin in Plasma (Cmax)1290 ± 25.01300 ± 21.41010 ± 31.11020 ± 32.81170 ± 33.31150 ± 32.6
Statistical analysis
  • FDC 25 Fed (T1) vs E25+L5+M1000 Fed (R1) · Ratio (%): 97.97 · 90% CI 91.46 to 104.94Relative bioavailability was estimated by the adjusted gMean ratio of T1 divided by R1. Standard deviation is actually intra-individual geometric coefficient variation (gCV).
  • FDC 25 Fast (T2) vs E25+L5+M1000 Fast (R2) · Ratio (%): 100.04 · 90% CI 90.23 to 110.91Relative bioavailability was estimated by the adjusted gMean ratio of T2 divided by R2. Standard deviation is actually intra-individual geometric coefficient variation (gCV).
  • FDC 10 Fed (T3) vs E10+L5+M1000 Fed (R3) · Ratio (%): 101.24 · 90% CI 94.58 to 108.38Relative bioavailability was estimated by the adjusted gMean ratio of T3 divided by R3. Standard deviation is actually intra-individual geometric coefficient variation (gCV).
PrimaryMaximum Measured Concentration of Linagliptin in Plasma (Cmax)

Maximum measured concentration of Linagliptin in plasma (Cmax) is presented

Time frame:
1.5 hours (h) before drug administration and 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 5h, 6h, 7h, 8h,10h, 12h, 24h, 34h, 48h, and 72h after drug administration
Reported as:
Geometric mean · nmol/L
Maximum Measured Concentration of Linagliptin in Plasma (Cmax)
nmol/LFDC 25 Fed (T1)E25+L5+M1000 Fed (R1)FDC 25 Fast (T2)E25+L5+M1000 Fast (R2)FDC 10 Fed (T3)E10+L5+M1000 Fed (R3)
Maximum Measured Concentration of Linagliptin in Plasma (Cmax)6.37 ± 20.66.51 ± 19.49.66 ± 44.58.35 ± 27.26.25 ± 23.16.15 ± 22.8
Statistical analysis
  • FDC 25 Fed (T1) vs E25+L5+M1000 Fed (R1) · Ratio (%): 97.50 · 90% CI 89.94 to 105.71Relative bioavailability was estimated by the adjusted gMean ratio of T1 divided by R1. Standard deviation is actually intra-individual geometric coefficient variation (gCV).
  • FDC 25 Fast (T2) vs E25+L5+M1000 Fast (R2) · Ratio (%): 117.31 · 90% CI 103.41 to 133.07Relative bioavailability was estimated by the adjusted gMean ratio of T2 divided by R2. Standard deviation is actually intra-individual geometric coefficient variation (gCV).
  • FDC 10 Fed (T3) vs E10+L5+M1000 Fed (R3) · Ratio (%): 102.74 · 90% CI 98.56 to 107.10Relative bioavailability was estimated by the adjusted gMean ratio of T3 divided by R3. Standard deviation is actually intra-individual geometric coefficient variation (gCV).
PrimaryArea Under the Concentration-time Curve of Linagliptin in Plasma Over the Time Interval From 0 to 72 Hours (AUC0-72)

Area under the concentration-time curve of Linagliptin in plasma over the time interval from 0 to 72 hours (AUC0-72) is presented

Time frame:
1.5 hours (h) before drug administration and 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 5h, 6h, 7h, 8h,10h, 12h, 24h, 34h, 48h, and 72h after drug administration
Reported as:
Geometric mean · nmol*h/L
Area Under the Concentration-time Curve of Linagliptin in Plasma Over the Time Interval From 0 to 72 Hours (AUC0-72)
nmol*h/LFDC 25 Fed (T1)E25+L5+M1000 Fed (R1)FDC 25 Fast (T2)E25+L5+M1000 Fast (R2)FDC 10 Fed (T3)E10+L5+M1000 Fed (R3)
Area Under the Concentration-time Curve of Linagliptin in Plasma Over the Time Interval From 0 to 72 Hours (AUC0-72)273 ± 18.7282 ± 17.2290 ± 24.7276 ± 21.1258 ± 25.1260 ± 20.2
Statistical analysis
  • FDC 25 Fed (T1) vs E25+L5+M1000 Fed (R1) · Ratio (%): 96.34 · 90% CI 92.13 to 100.75Relative bioavailability was estimated by the adjusted gMean ratio of T1 divided by R1. Standard deviation is actually intra-individual geometric coefficient variation (gCV).
  • FDC 25 Fast (T2) vs E25+L5+M1000 Fast (R2) · Ratio (%): 105.07 · 90% CI 99.95 to 110.45Relative bioavailability was estimated by the adjusted gMean ratio of T2 divided by R2. Standard deviation is actually intra-individual geometric coefficient variation (gCV).
  • FDC 10 Fed (T3) vs E10+L5+M1000 Fed (R3) · Ratio (%): 100.31 · 90% CI 96.41 to 104.38Relative bioavailability was estimated by the adjusted gMean ratio of T3 divided by R3. Standard deviation is actually intra-individual geometric coefficient variation (gCV).
SecondaryArea Under the Concentration-time Curve of the Empagliflozin in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)

Area under the concentration-time curve of the Empagliflozin in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞) is presented

Time frame:
1.5 hours (h) before drug administration and 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 5h, 6h, 7h, 8h,10h, 12h, 24h, 34h, 48h, and 72h after drug administration
Reported as:
Geometric mean · nmol*h/L
Area Under the Concentration-time Curve of the Empagliflozin in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)
nmol*h/LFDC 25 Fed (T1)E25+L5+M1000 Fed (R1)FDC 25 Fast (T2)E25+L5+M1000 Fast (R2)FDC 10 Fed (T3)E10+L5+M1000 Fed (R3)
Area Under the Concentration-time Curve of the Empagliflozin in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)6060 ± 25.76190 ± 22.56490 ± 20.06300 ± 18.72130 ± 15.52180 ± 15.4
Statistical analysis
  • FDC 25 Fed (T1) vs E25+L5+M1000 Fed (R1) · Ratio (%): 96.63 · 90% CI 92.86 to 100.54Relative bioavailability was estimated by the adjusted gMean ratio of T1 divided by R1. Standard deviation is actually intra-individual geometric coefficient variation (gCV).
  • FDC 25 Fast (T2) vs E25+L5+M1000 Fast (R2) · Ratio (%): 100.87 · 90% CI 97.96 to 103.86Relative bioavailability was estimated by the adjusted gMean ratio of T2 divided by R2. Standard deviation is actually intra-individual geometric coefficient variation (gCV).
  • FDC 10 Fed (T3) vs E10+L5+M1000 Fed (R3) · Ratio (%): 99.75 · 90% CI 95.81 to 103.86Relative bioavailability was estimated by the adjusted gMean ratio of T3 divided by R3. Standard deviation is actually intra-individual geometric coefficient variation (gCV).
SecondaryArea Under the Concentration-time Curve of the Metformin in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)

Area under the concentration-time curve of the Metformin in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞) is presented

Time frame:
1.5 hours (h) before drug administration and 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 5h, 6h, 7h, 8h,10h, 12h, 24h, 34h, 48h, and 72h after drug administration
Reported as:
Geometric mean · ng*h/mL
Area Under the Concentration-time Curve of the Metformin in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)
ng*h/mLFDC 25 Fed (T1)E25+L5+M1000 Fed (R1)FDC 25 Fast (T2)E25+L5+M1000 Fast (R2)FDC 10 Fed (T3)E10+L5+M1000 Fed (R3)
Area Under the Concentration-time Curve of the Metformin in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)14100 ± 29.314100 ± 30.08260 ± 29.28600 ± 33.212200 ± 25.812400 ± 25.0
Statistical analysis
  • FDC 25 Fed (T1) vs E25+L5+M1000 Fed (R1) · Ratio (%): 96.57 · 90% CI 90.94 to 102.56Relative bioavailability was estimated by the adjusted gMean ratio of T1 divided by R1. Standard deviation is actually intra-individual geometric coefficient variation (gCV).
  • FDC 25 Fast (T2) vs E25+L5+M1000 Fast (R2) · Ratio (%): 95.40 · 90% CI 87.50 to 104.01Relative bioavailability was estimated by the adjusted gMean ratio of T2 divided by R2. Standard deviation is actually intra-individual geometric coefficient variation (gCV).
  • FDC 10 Fed (T3) vs E10+L5+M1000 Fed (R3) · Ratio (%): 98.45 · 90% CI 92.44 to 104.85Relative bioavailability was estimated by the adjusted gMean ratio of T3 divided by R3. Standard deviation is actually intra-individual geometric coefficient variation (gCV).
SecondaryArea Under the Concentration-time Curve of the Linagliptin in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)

Area under the concentration-time curve of the Linagliptin in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞) is presented

Time frame:
1.5 hours (h) before drug administration and 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 5h, 6h, 7h, 8h,10h, 12h, 24h, 34h, 48h, and 72h after drug administration
Reported as:
Geometric mean · nmol*h/L
Area Under the Concentration-time Curve of the Linagliptin in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)
nmol*h/LFDC 25 Fed (T1)E25+L5+M1000 Fed (R1)FDC 25 Fast (T2)E25+L5+M1000 Fast (R2)FDC 10 Fed (T3)E10+L5+M1000 Fed (R3)
Area Under the Concentration-time Curve of the Linagliptin in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)465 ± 27.2483 ± 24.8477 ± 31.1443 ± 25.2424 ± 27.6420 ± 27.1
Statistical analysis
  • FDC 25 Fed (T1) vs E25+L5+M1000 Fed (R1) · Ratio (%): 95.08 · 90% CI 87.36 to 103.48Relative bioavailability was estimated by the adjusted gMean ratio of T1 divided by R1. Standard deviation is actually intra-individual geometric coefficient variation (gCV).
  • FDC 25 Fast (T2) vs E25+L5+M1000 Fast (R2) · Ratio (%): 105.72 · 90% CI 98.78 to 113.15Relative bioavailability was estimated by the adjusted gMean ratio of T2 divided by R2. Standard deviation is actually intra-individual geometric coefficient variation (gCV).
  • FDC 10 Fed (T3) vs E10+L5+M1000 Fed (R3) · Ratio (%): 101.61 · 90% CI 92.00 to 112.22Relative bioavailability was estimated by the adjusted gMean ratio of T3 divided by R3. Standard deviation is actually intra-individual geometric coefficient variation (gCV).

Adverse events

Collected over Adverse events occurring up to 168 hours after intake of trial drug administration in each treatment period were assigned to treatment. Adverse events were collected up to 42 days per participant.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
FDC 25 Fed (T1)—0/15 (0%)5/15 (33.3%)
E25+L5+M1000 Fed (R1)—0/14 (0%)4/14 (28.6%)
FDC 25 Fast (T2)—0/20 (0%)6/20 (30%)
E25+L5+M1000 Fast (R2)—0/18 (0%)4/18 (22.2%)
FDC 10 Fed (T3)—0/14 (0%)1/14 (7.1%)
E10+L5+M1000 Fed (R3)—0/15 (0%)4/15 (26.7%)
Most frequent other events
Most frequent other events
EventFDC 25 Fed (T1)E25+L5+M1000 Fed (R1)FDC 25 Fast (T2)E25+L5+M1000 Fast (R2)FDC 10 Fed (T3)E10+L5+M1000 Fed (R3)
HeadacheNervous system disorders2/152/143/203/181/142/15
NauseaGastrointestinal disorders1/152/141/200/180/142/15
DiarrhoeaGastrointestinal disorders0/150/140/201/180/142/15
DizzinessNervous system disorders1/151/141/200/180/141/15
Oropharyngeal painRespiratory, thoracic and mediastinal disorders0/151/140/200/180/140/15
Blister ruptureSkin and subcutaneous tissue disorders0/151/140/200/180/140/15
Abdominal pain upperGastrointestinal disorders0/150/141/200/180/141/15
VomitingGastrointestinal disorders1/150/140/200/180/140/15
Decreased appetiteMetabolism and nutrition disorders0/150/140/200/180/141/15
NasopharyngitisInfections and infestations0/150/140/201/180/140/15

Baseline characteristics

Treated set (TS): This subject set included all randomised subjects, whether treated or not, who were documented to have received at least 1 dose of study drug. This is the full analysis set population in the sense of ICH E9.

Age, Continuous
Age, Continuous(years)FDC 25 Fed (T1)/ E25+L5+M1000 Fed (R1) (Part 1)E25+L5+M1000 Fed (R1)/ FDC 25 Fed (T1) (Part 1)FDC 25 Fast (T2)/ E25+L5+M1000 Fast (R2) (Part 2)E25+L5+M1000 Fast (R2)/ FDC 25 Fast (T2) (Part 2)FDC 10 Fed (T3)/ E10+L5+M1000 Fed (R3) (Part 3)E10+L5+M1000 Fed (R3)/ FDC 10 Fed (T3) (Part 3)Total
Mean36.7 ± 8.937.1 ± 11.936.2 ± 12.334.1 ± 10.037.3 ± 11.935.3 ± 9.436.0 ± 10.4
Sex: Female, Male
Sex: Female, Male(Participants)FDC 25 Fed (T1)/ E25+L5+M1000 Fed (R1) (Part 1)E25+L5+M1000 Fed (R1)/ FDC 25 Fed (T1) (Part 1)FDC 25 Fast (T2)/ E25+L5+M1000 Fast (R2) (Part 2)E25+L5+M1000 Fast (R2)/ FDC 25 Fast (T2) (Part 2)FDC 10 Fed (T3)/ E10+L5+M1000 Fed (R3) (Part 3)E10+L5+M1000 Fed (R3)/ FDC 10 Fed (T3) (Part 3)Total
Female34724121
Male44383729
08

Study locations

1 site
  • Humanpharmakologisches Zentrum Biberach
    Biberach, 88397, Germany
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2016 to primary completion in Oct 2016, 2 months.

Results were first posted in Feb 2020, 3 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2016
First posted
Jul 4, 2016
StartActual
Jul 20, 2016
Primary completionActual
Oct 1, 2016
CompletionActual
Oct 31, 2016
Results first posted
Feb 21, 2020
Last update
Mar 5, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02821910
Responsible party
Sponsor
First posted
Jul 4, 2016
Start date
Jul 20, 2016
Primary completion
Oct 1, 2016
Completion
Oct 31, 2016
Results posted
Feb 21, 2020
Last update
Mar 5, 2020

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion